Our Platform | Amyloid Oligomers - Alzheon | Preserving Future Memories
Biogen Results: Time To Change The Paradigm In Alzheimer's Disease (NASDAQ:BIIB) | Seeking Alpha
IJMS | Free Full-Text | Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease | HTML
Current clinical trials for the treatment of Alzheimer's disease (as of... | Download Table
P4‐704: BAN2401 SHOWS STRONGER BINDING TO SOLUBLE AGGREGATED AMYLOID‐BETA SPECIES THAN ADUCANUMAB - Lannfelt - 2019 - Alzheimer's & Dementia - Wiley Online Library
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment | Expert Reviews in Molecular Medicine | Cambridge Core
Biogen and Eisai try to defend Alzheimer's drug BAN2401 against skeptics | Fierce Biotech
Alzheimer's disease drug development pipeline: 2017 - Cummings - 2017 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
Chad Swanson, PhD, on the Promising Effect of BAN2401 on Alzheimer Disease Progression
The Development of Pharmacological Therapies for Alzheimer's Disease | SpringerLink
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval | Semantic Scholar
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise - Biological Psychiatry
Lecanemab Reduces Blood Biomarkers of Alzheimer Disease - Practical Neurology
Frontiers | Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease | Frontiers in Computational Neuroscience
LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Advisory Council January 2018 Meeting Presentation: Overview on NIA Preclinical Pipeline | ASPE
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE | News Release：2010 | Eisai Co., Ltd.
Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401's Mechanism of Action
Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401) - touchNEUROLOGY
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease | Nature Reviews Neurology
Frontiers | Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease | Neuroscience
BioArctic's new collaboration with Eisai on BAN2401
